vTv Therapeutics: vTv Therapeutics' stock plunges after FDA pauses High Point company's diabetes drug development

After things were looking up for High Point's vTv Therapeutics in the spring, including the raising of $51 million, it has encountered another serious obstacle with its diabetes drug development. Here's what the FDA's pause means for the biopharmaceutical company.